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Abstract
Background: Conotruncal heart defects (CTDs) are present in 75-85% of patients suffering from the 22q11.2
deletion syndrome. To date, no consistent phenotype has been consistently correlated with the 22q11.2 deletions.
Genetic studies have implicated TBX1 as a critical gene in the pathogenesis of the syndrome. The aim of study was
to determine the incidence of the 22q11.2 deletion in Chinese patients with CTDs and the possible mechanism for
pathogenesis of CTDs.
Methods: We enrolled 212 patients with CTDs and 139 unrelated healthy controls. Both karyotypic analysis and
multiplex ligation-dependent probe amplification were performed for all CTDs patients. Fluorescence in situ
hybridization was performed for the patients with genetic deletions and their relatives. The TBX1 gene was
sequenced for all patients and healthy controls. The c
2 and Fisher’s exact test were used in the statistical analysis.
Results: Thirteen of the 212 patients with CTDs (6.13%) were found to have the 22q11.2 deletion syndrome. Of the
13 cases, 11 presented with a hemizygous interstitial microdeletion from CLTCL1 to LZTR1; one presented with a
regional deletion from CLTCL1 to DRCR8; and one presented with a regional deletion from CDC45L to LZTR1. There
were eight sequence variants in the haploid TBX1 genes of the del22q11 CTDs patients. The frequency of one
single nucleotide polymorphism (SNP) in the del22q11 patients was different from that of the non-del patients (P
< 0.05), and the frequencies of two other SNPs were different between the non-del CTDs patients and controls (P
< 0.05).
Conclusions: CTDs, especially pulmonary atresia with ventricular septal defect and tetralogy of Fallot, are the most
common disorders associated with the 22q11.2 deletion syndrome. Those patients with both CTDs and 22q11.2
deletion generally have a typical or atypical deletion region within the TBX1 gene. Our results indicate that TBX1
genetic variants may be associated with CTDs.
Background
Congenital heart defects (CHDs) comprise a group of
structural abnormalities with a combined incidence rate
of approximately 1% of all live births. Of the cases of
CHDs, 15-20% are conotruncal heart defects (CTDs) [1].
CTDs share the morphological architecture of the
presence of ventricular outflow tract defects. They
include tetralogy of Fallot (TOF), pulmonary atresia
with ventricular septal defect (PA/VSD), double outlet
of right ventricular (DORV), transposition of the great
arteries (TGA), persistent truncus arteriosus (PTA) and
interrupted aortic arch (IAA).
Although CTDs are generally considered complex,
multifactorial disorders, a number of familial cases sug-
gesting Mendelian inheritance have been described. The
DiGeorge/Velo-cardio-facial syndrome (DGS/VCFS) is a
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75-85% of the deletion patients present with a CTD.
Reports originating from Western countries associate
12.8-17.8% of their CTD cases to the 22q11.2 deletion
[2-5]. Most of the 22q11.2 deletions are sporadic in ori-
gin; however, approximately 10% of the deletions are
inherited [6]. In total, 84-90% of the patients have a
common region of deletion that is approximately 3 Mb
deletion, which contains about 40 genes; while 7-14%
present with a smaller, less common proximal ~1.5 Mb
nested deletion, containing about 30 genes [7]. The
deletions are reported to occur as a result of a non-alle-
lic homologous recombination between the low-copy
repeats (LCRs) in the 22q11.2 region [8,9]. A minority
of patients have smaller overlapping and non-overlap-
ping 22q11.2 deletions [10].
The TBX1 gene maps to the 1.5 Mb typically deleted
region associated with DGS/VCFS and encodes a tran-
scription factor of the T-box family known to play an
important role in the regulation of developmental pro-
cesses [11]. A TBX1 haploinsufficiency is thought to
be responsible for many of the phenotypic traits of
the DGS/VCFS. Mutations of the TBX1 gene have
been detected in some patients featuring DGS/VCFS
who are otherwise devoid of the 22q11.2 deletion
[12-14].
Our previous screening for 22q11.2 deletions in 24
Chinese patients with CTDs by fluorescence in situ
hybridization (FISH) showed a lower incidence rate
(4.2%) of del22q11 than that usually reported (12.8-
17.8%) [2-5,15]. In order to better understand the inci-
dence of del22q11 in Chinese patients with CTDs, we
carried out this current study in a new population of
212 patients.
Methods
Subjects
All assessments were undertaken with the approval of
the Medical Ethics Committee of the Shanghai Chil-
dren’s Medical Center (SCMC). Patients were recruited
prospectively from June 2008 to December 2009 at the
SCMC. A total of 212 patients with CTDs were enrolled,
of whom 92 were female and 120 male. The median age
was 2.69 years old, and all of the patients were of the
H a ne t h n i c i t y .T h e yi n c l u d e d7 4T O F ,5 1D O R V ,3 5
PA/VSD, 28 TGA, 4 IAA and 3 PTA patients as well as
17 other cases of conotruncal malformations (Figure 1).
Diagnoses were confirmed by transthoracic echocardio-
graphy and cardiac catheterization. When available, the
surgical operative notes were reviewed. Extracardiac
anomalies were also evaluated. Informed written paren-
tal consents were obtained for all of the patients partici-
pating in the study before blood samples were drawn at
the time of catheterization.
Normal controls included 139 unrelated healthy Chi-
nese children (57 female, 82 male; all ethnically Han)
for detecting genetic variations at the TBX1 locus. The
median age was 7.43 years old. The cardiac morphology
of these controls was confirmed to be normal by trans-
thoracic echocardiography at the SCMC. After obtaining
informed written parental consent, a peripheral venous
blood sample was collected into an anticoagulation tube
with sodium citrate. Genomic DNA was extracted from
peripheral lymphocytes using a QIAamp DNA Blood
Mini Kit in keeping with the manufacturer’s instructions
(Qiagen, Duesseldorf, Germany).
Cell culture and karyotyping
The karyotypes were examined using GTG-banding at a
400 band level. The lymphocytes obtained from the per-
ipheral blood of the patients were cultured at 37°C with
5% CO2. The slide preparation for karyotyping was per-
formed using the cultured peripheral blood cells. The
G-banding was performed on these slides using a modi-
fication of Seabright’s technique [16]. In each case, at
least 20 banded metaphases with good chromosome
separation were analyzed by experienced geneticists.
Multiplex ligation-dependent probe amplification (MLPA)
Genomic DNA was extracted from peripheral lympho-
cytes using a QIAamp DNA Blood Mini Kit according
to the manufacturer’s instructions (Qiagen). For detec-
tion of the 22q11.2 deletion, we used a commercial
Figure 1 Distribution of phenotypes of cardiac anomalies in
patients with CTDs in this study. Abbreviations: TOF: tetrology of
Fallot; DORV: Double outlet of right ventricle; PA/VSD: pulmonary
atresia/ventricular septal defect; TGA: transposition of the great
arteries; PTA: persistent truncus arteriosus; IAA: interruption of aortic
arch; VSD: ventricular septal defect; HDHS: hypoplastic right heart
syndrome; COA: coarctation of aorta; SV/MGA: single ventricle/
malposition of great arteries.
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Page 2 of 9SALSA P250-A1 MLPA-DiGeorge syndrome test kit
(MRC-Holland, Amsterdam, The Netherlands). The
P250-A1 MLPA probemix contains 48 probes for the
frequent 22q11 deletion regions and the infrequent dele-
tion regions. These probes are capable of distinguishing
the most common types of deletion, 30 of which are
related to the chromosomal region of 22q11. Five probes
cover the Cat Eye Syndrome (CES) region, and another
14 fall on the most common DiGiorge deletion region.
The 30 probes hybridize to a 7.3 Mb genomic region on
chromosome 22q11. The most commonly deleted region
starts at probe CLTCL1,d o w n s t r e a mo fL C R - A ,a n d
ends at probe LZTR1, upstream of LCR-D. The genomic
distance between probes CLTCL1 and LZTR1 is
approximately 2.2-2.5 Mb (Fi g u r e2 ) .T h er e m a i n i n g1 8
probes are located on 22q13, 10p15, 8p23, 4q34-qter,
9q34.3 and 17p13.3.
The MLPA reactions were performed following the
manufacturer’s instructions on all CTDs patients. After
denaturation, hybridization, ligation and amplification,
the polymerase chain reaction (PCR) products were
sequenced by capillary electrophoresis using an ABI
3130 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). The raw data from electrophoresis were
imported into the GeneMapper 4.0 software program
(Applied Biosystems) and then analyzed using the Coffa-
lyser MLPA DAT software package (MRC-Holland).
After normalization, the data were compared to a
synthetic control sample, which represents the median
of all normal samples in each experiment. A threshold
of signal intensity change of <0.75 was used to identify
potential deletions, and a threshold of >1.33 was used to
identify potential duplications. All samples with poten-
tial deletions or duplications were re-analyzed by MLPA.
FISH
The 22q11.2 deletions detected in patients by MLPA
were confirmed by FISH analysis. Commercially avail-
able locus specific probe kits N25 and TUPLE1 were
purchased from Vysis (Downers Grove, IL, USA). The
N25 kit contains the spectrum orange N25 (D22S75)
probe for 22q11.2 and the spectrum green ARSA gene
control probe for 22q13.3. The TUPLE1 kit contains the
spectrum orange TUPLE1 (HIRA) probe at 22q11.2 and
the spectrum green TelVysion 22q probe at 22q13.3.
The FISH probes N25 (D22S75)a n dTUPLE1 (HIRA)
both lie within the DiGeorge chromosomal region
(DGCR). The probe TUPLE1 is located between
CLTCL1 and D22S941 and overlaps with the P250-A1
MLPA probe HIRA in the chromosome. The N25
(D22S75) probe lies between the P250-A1 MLPA probe
DGCR2 and CLTCL1 (Figure 2).
Dual-color FISH was performed on metaphase spreads of
peripheral blood lymphocytes on pre-cleaned glass slides.
Co-denaturation of probes and slides was performed at 73°
C for 5 min, followed by overnight hybridization at 42°C.
After hybridization and washing, chromosomes and nuclei
were counterstained with DAPI (Vysis, Downers Grove, IL,
USA). A coverslip was then applied to each slide. Images
were captured using a CCD camera (ProgRes, Jena, Ger-
many) through an Olympus-BX51 fluorescence microscope
(Olympus, Japan) with the VideoTest Fish 2.0 software
package (GP Medical Technologies Ltd, Beijing, China).
Generally, 10 to 20 metaphases were examined, and 30 to
50 interphase nuclei were scored for the number of signals
present for each probe.
Gene PCR and sequencing
The three different splice variants of the TBX1 coding
regions–including exon-intron boundaries and the promo-
ter site–were amplified in the 212 CTD patients and 139
unrelated healthy controls. Primers were designed follow-
ing the corresponding genomic regions available from the
GenBank database (NG_009229.10) using Primer3 soft-
ware (http://frodo.wi.mit.edu/primer3/). All PCR products
were sequenced on an ABI 3130 sequencer (Applied Bio-
systems). The sequence traces were aligned with the refer-
ence sequence using the GenBank BLAST program.
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) and allele fre-
quencies were assessed at each single nucleotide
Figure 2 Genomic map of the 22q11.2 region based on human
genome overview page (Build 37.1). The relative positions of
LCR22s and ranges of LCR22-A, -B, -C, and -D, as defined by Shaikh
et al. [5], are depicted. The FISH probes N25 (D22S75) and TUPLE1
are marked on the LCR22s. The 3 Mb and 1.5 Mb typical deletion
regions are shown in yellow. The MLPA probes were arranged
according to the manufacturer’s product information (MRC-Holland)
and the position of the related gene in chromosome 22q11.2. The
three types of deletion regions are delineated as Type I, Type II, and
Type III, corresponding to the N25(D22S75)t oLZTR1, CDC45L to
LZTR1, and N25(D22S75)t oLZTR1, respectively. The red lines indicate
the deletion regions detected by MLPA analysis, whereas the blue
lines designate the results of the FISH analysis.
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2 and Fisher’s
exact test. HWE_P value > 0.05 was considered as a sta-
tistically insignificant deviation from the equilibrium.
The 2-sided statistical tests were considered significant
with a level of P ≤ 0.05. All statistical analyses in our
study were carried out with SPSS 11.5 (SPSS Inc. Chi-
cago, IL, USA).
Results
Cell culture and karyotyping
No obvious structural and numerical abnormalities were
found on the metaphase spreads of the 212 patients.
Multiplex ligation-dependent probe amplification
MLPA screening identified a loss of DNA dosage in
chromosome 22q11 in 13 subjects (6.13%) out of the
212 CTD patients screened (Table 1), an incidence
lower than that reported (12.8-17.8%) by authors in the
West [2-5]. Of these 13 subjects, 11 were found to have
an identical deletion region about 2.2-2.5 Mb in size,
spanning from probe CLTCL1 to LZTR1 (LCR22-A to
LCR22-D) (Figures 2 and 3). Patient NO.10D differed in
that he showed a deletion region about 1.8-2.0 Mb in
size, from CDC45L to LZTR1 (atypical LCR22-A to
LCR22-D) (Figures 2 and 3). In patient NO.13, we
found yet a smaller deletion region about 0.9-1.3 Mb in
size, extending from CLTCL1 to DGCR8 (LCR22-A to
LCR22-B) (Figures 2 and 3). Other probes assaying for
deletions in chromosome 4p, 8p, 9p, 10p and 17p did
not reveal obvious changes in the number of copies.
FISH
Of the 13 patients with deletions identified by MLPA,
12 were confirmed by using two FISH probes. FISH
examination of their family members indicated that the
deletions arose de novo. In patient NO.10D, with a dele-
tion region from CDC45L to LZTR1, the signals of both
probes N25 (D22S75)a n dTUPLE1 were detected in the
FISH slides (data not shown).
From the combined results of MLPA and FISH, two of
the deletion regions could be redefined from N25
(D22S75)t oLZTR1 and from N25 (D22S75)t oDGCR8.
The proximal breakpoint of the deletion region from
CDC45L to LZTR1 may be located on or neighboring
CDC45L, which is at locus 0.03 Mb to HIRA (TUPLE1)
(Figure 2).
Table 1 Detailed information of the 13 CTD patients with 22q11.2 deletion
NO. Age* Cardiac Defects Karyotype Size of FISH TBX1
(m) Primary Diagnosis Deletion (MLPA) N25 TUPLE1 Sequence
T36 21 TOF 46,XY CLTCL1-LZTR1 Del Del H
1E 13 TOF 46,XX CLTCL1-LZTR1 Del Del H
2F 19 TOF 46,XY CLTCL1-LZTR1 Del Del H
33 24 TOF 46,XX CLTCL1-LZTR1 Del Del H
18 8 PA/VSD 46,XY CLTCL1-LZTR1 Del Del H
1C 4 PA/VSD 46,XX CLTCL1-LZTR1 Del Del H
32 23 PA/VSD 46,XY CLTCL1-LZTR1 Del Del H
1I 15 PA/VSD 46,XY CLTCL1-LZTR1 Del Del H
2D 23 PA/VSD 46,XX CLTCL1-LZTR1 Del Del H
5 9 PA/VSD 46,XY CLTCL1-LZTR1 Del Del H
10D 120 PA/VSD 46,XY CDC45L-LZTR1 N N H
D2 21 DORV 46,XY CLTCL1-LZTR1 Del Del H
13 8 PTA(A1) 46,XX CLTCL1-DGCR8 Del Del H
Abbreviations: * age in months at the time of examination; m = months; Del = deletion; N = normal; H = haploid
Figure 3 MLPA ratio charts of the normal control and the
three deletion types. The X-axis shows the names of the probes,
whereas the Y-axis indicates their ratios. All results were confirmed
in two independent runs.
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Table 2 lists the clinical manifestations (cardiac and
extracardiac anomalies) of the 13 CTD patients deter-
mined to have the 22q11.2 deletion, including seven
patients with PA/VSD, four with TOF, one with PTA
and one with DORV; meanwhile, none of the TGA and
IAA patients had such deletions. Of the patients with
deletions, eight suffered from right aortic arch (RAA) or
aortopulmonary collateral arteries (APCAs), and six
from extracardiac anomalies.
Gene PCR and sequencing
In the 22q11.2 deletion group, no heterozygotes of
TBX1 were detected, which is in accordance with the
partial monosomy for 22q11.2. No mutations were
detected in the haploid TBX1 gene. However, eight dif-
ferent sequence variants were detected in the haploid
TBX1 gene of the 13 del22q11 patients (Figure 4). The
allele frequencies of SNPs observed in our study were
s i m i l a rt ot h a to b s e r v e di nt h eH a nC h i n e s eo f1 0 0 0
Genome Project Database (http://browser.1000genomes.
Table 2 Clinical manifestations of the 13 CTD patients with 22q11.2 deletion
NO. Age* Size of Cardiac defects Extracaridac anomalies
(m) Deletion P.D. S.D.
T36 21 D22S75-LZTR1 TOF PFO/RAA Nil
1E 13 D22S75-LZTR1 TOF PFO/APCA Asymmetric cry/smile face
2F 19 D22S75-LZTR1 TOF PFO/RAA/APCA Nil
33 24 D22S75-LZTR1 TOF ASD(II) Nil
18 8 D22S75-LZTR1 PA/VSD PDA/ASD(II) Hypoplastic thymus
1C 4 D22S75-LZTR1 PA/VSD PFO/APCA Cleft palate
32 23 D22S75-LZTR1 PA/VSD PFO/PDA/APCA Classic dysmorphological facial features; hypoplastic thymus
1I 15 D22S75-LZTR1 PA/VSD PDA Nil
2D 23 D22S75-LZTR1 PA/VSD PDA/ASD/MAPCA Classic dysmorphological facial features
5 9 D22S75-LZTR1 PA/VSD ASD(II)/MAPCA inguinal hernia
10D 120 CDC45L-LZTR1 PA/VSD PDA/ASD/APCA Nil
D2 21 D22S75-LZTR1 DORV VSD/PS Nil
13 8 D22S75-DGCR8 PTA(A1) VSD Nil
Abbreviations: * age in months at the point of examination; m = months P.D. = primary diagnosis; S.D. = secondary diagnosis; ASD (II) = secondary atrial septal
defect; APCA = aortic-pulmonary collateral arteries; MAPCA = major aortic-pulmonary collateral artery; PDA = patent ductus arteriosus; PFO = Patent Foramen
Ovale; RAA = right aortic arch; PS = pulmonary stenosis.
Figure 4 Positions of common variants of the 13 patients with 22q11.2 deletion. Ancestral alleles are written with small letters. The
numerals from I to VIII are representative of the eight SNPs from rs5748417 to rs5746826, respectively. The corresponding identification numbers
of the 13 patients with 22q11.2 deletions are listed at the left.
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the non-deletion patients and healthy controls. All of
the substitutions were common variants with a minor
allele frequency (MAF) of > 0.05. All variants, except for
rs41298840 (c.933A > G, A311A), were detected at simi-
lar frequencies between del22q11 and non-del CTD
patients (Table 3). The frequencies of polymorphisms
c.933A > G were similar between the non-del22q11
CTD patients and the healthy controls, but they differed
from that of the del22q11 CTD patients (P <0 . 0 5 )
(Table 3).
The frequencies of rs5748417 (c.-87+242T > C) and
rs5748418 (c.-87+256G > A), as shown in Table 4, were
similar between the del22q11 CTD patients and
Table 3 Allele frequencies of SNPs in del22q11 patients (n = 13), non-del patients (n = 199), controls (n = 139) and
Han Chinese in 1000 Genome Project (n = 197)
SNP
$A F (%(n))
$A F (%(n))
$A F (%(n))
$A F (%(n))
del non-del non-del control del control control
#1000GPD
rs5748417
T 53.8(7) 68.6(273) 68.6(273) 59.0(164) 53.8(7) 59.0(164) 59.0(164) 66.0(260)
C 46.2(6) 31.4(125) 31.4(125) 41.0(114) 46.2(6) 41.0(114) 41.0(114) 34.0(134)
c
2 1.261 6.600 0.136 3.427
*P(df = 1) 0.363 0.011 0.777 0.074
rs5748418
G 53.8(7) 72.9(290) 72.9(290) 59.0(164) 53.8(7) 59.0(164) 59.0(164) 66.0(260)
A 46.2(6) 27.1(108) 27.1(108) 41.0(114) 46.2(6) 41.0(114) 41.0(114) 34.0(134)
c
2 2.272 14.28 0.136 3.427
*P(df = 1) 0.203 2.0E-4 0.777 0.074
rs737868
G 46.2(6) 31.7(126) 31.7(126) 38.8(108) 46.2(6) 38.8(108) 38.8(108) 39.8(157)
C 53.8(7) 68.3(272) 68.3(272) 61.2(170) 53.8(7) 61.2(170) 61.2(170) 60.2(237)
c
2 1.213 3.739 0.278 0.068
*P(df = 1) 0.364 0.059 0.772 0.081
rs41298814
T 61.5(8) 46.2(184) 46.2(184) 51.8(144) 61.5(8) 51.8(144) 51.8(144) 51.5(203)
C 38.5(5) 53.8(214) 53.8(214) 48.2(134) 38.5(5) 48.2(134) 48.2(134) 48.5(191)
c
2 1.185 2.031 0.472 0.005
*P(df = 1) 0.398 0.160 0.577 1.000
rs2301558
T 23.1(3) 14.8(59) 14.8(59) 14.4(40) 23.1(3) 14.4(40) 14.4(40) 12.4(49)
C 76.9(10) 85.2(339) 85.2(339) 85.6(238) 76.9(10) 85.6(238) 85.6(238) 87.6(345)
c
2 0.669 0.025 0.744 0.540
*P(df = 1) 0.426 0.912 0.744 0.489
rs41298840
A 76.9(10) 44.7(178) 44.7(178) 47.1(131) 76.9(10) 47.1(131) 47.1(131) 52.3(206)
G 23.1(3) 55.3(220) 55.3(220) 52.9(147) 23.1(3) 52.9(147) 52.9(147) 47.7(188)
c
2 5.275 0.379 4.416 1.737
*P(df = 1) 0.025 0.583 0.046 0.210
rs4819522
C 76.9(10) 86.3(344) 86.4(344) 86.3(240) 76.9(10) 86.3(240) 86.3(240) 87.1(343)
T 23.1(3) 13.6(54) 13.6(54) 13.7(38) 23.1(3) 13.7(38) 13.7(38) 12.9(51)
c
2 0.953 0.001 0.908 0.075
*P(df = 1) 0.403 1.000 0.404 0.818
rs5746826
G 53.8(7) 33.9(135) 33.9(135) 38.1(106) 53.8(7) 38.1(106) 38.1(106) 37.6(148)
T 46.2(6) 66.1(263) 66.1(263) 61.9(172) 46.2(6) 61.9(172) 61.9(172) 62.4(246)
c
2 2.211 1.264 1.292 0.022
*P(df = 1) 0.148 0.289 0.262 0.936
Abbreviation:
$A F indicates the allele frequency. * P-values were calculated using Fisher’s exact test.
#the 1000 Genome Project Database.
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between the non-del22q11 CTD patients and controls
(Table 3). The discrepancy may be due to the limited
sample size (n = 13) of the patients with CTDs and
del22q11. Further analysis of the three genotype fre-
quencies of the two SNPs between non-del22q11 CTD
patients and controls showed significant differences
between the two groups at both genetic polymorphisms
(Table 5).
In addition, the non-synonymous SNP rs41298838
(c.928G > A, G310S) was found to occur at a similar fre-
quency in both the non-del22q11 patients and healthy
controls (Table 4). This resu l ti si nc o n t r a s tw i t hap r e -
vious finding by Yagi et al. [12], who reported it as a muta-
tion. It is, however, in line with the study by Heike et al.,
who used SIFT and Polyphen to predict that this non-
synonymous SNP would be tolerated by the protein [17].
Discussion
Microdeletion in the 22q11 region causes a variety of
disorders, including the DiGeorge (DGS; OMIM
188400) and Velo-cardio-facial (VCFS; OMIM 192430)
syndrome. Summarized as a deletion syndrome
(22q11DS), it is the most frequent chromosomal micro-
deletion syndrome, occurring once in 4,000 live births
[18]. Applying FISH with commercially available N25
(D22S75)o rTUPLE1 probes located in the proximal
commonly deleted region of 22q11.2 is a proven method
for detection of the 22q11 deletion. Most of the 22q11.2
deletions can be found using FISH diagnostic probes,
although this method has failed to detect deletions that
a r ee i t h e rp r o x i m a lo rd i s t a lt ot h eF I S Hp r o b e su s e d
[7,19,20]. Methods employing multiple genetic markers
in the 22q11 region are increasingly important for the
accurate identification of genomic microdeletions.
MLPA analysis with multiple probes has been applied to
analyze the 22q11 chromosome in detail [21], and the
commercially available high-definition MLPA 22q11 kit
has proven to be a sensitive tool for detecting copy
number changes on the long arm of chromosome 22. In
our study, in one patient (NO.10D) who tested negative
for the 22q11.2 deletion using FISH probes N25
(D22S75)a n dTUPLE1, MLPA analysis actually identi-
fied an atypical deletion from CDC45L to CLTCL1.
In general, CTDs are the disorders most commonly
associated with the 22q11.2 deletion syndrome [22,23].
Of the study subjects, 20% (7/35) of those with PA/
VSD, 5.4% (4/74) with TOF, 33% (1/3) with PTA and
2% (1/51) with DORV were detected to have the
22q11.2 deletion. None of the patients with TGA had
the 22q11.2 deletion. In the subgroup of patients pre-
senting with the 22q11.2 deletion, 53.8% (7/13) suffered
from PA/VSD, 30.8% (4/13) from TOF, and 69.2% from
RAA or APCAs (Table 1 and 2). This result is in line
with the findings of previous studies, which concluded
t h a tah i g hp r e v a l e n c eo ft h ed e l e t i o ni sn o t e di n
patients with TOF, PA/VSD, PTA, as well as RAA and
major APCAs [23,24]. Despite its commonness in
patients with the 22q11.2 deletion in previous studies
[25-27], none of the patients with the IAA condition
examined in this study showed this deletion. This find-
ing may be due to the small number (n = 4) of IAA
patients investigated or to possible differences in the
22q11DS pathoanatomy between Western and Asian
populations. Further investigation of the deletion in a
larger sample size of IAA patients is necessary to clarify
this issue.
Table 4 Allele frequencies of rs41298838 (c.928G > A, G310S) in the three groups
SNP Allele Frequency (%(n)) Allele Frequency (%(n)) Allele Frequency (%(n))
del non-del non-del control del control
G 100(13) 95.7(382) 95.7(382) 97.5(271) 100(13) 97.5(271)
A 0(0) 4.3(17) 4.3(17) 2.5(7) 0(0) 2.5(7)
c
2 1.578 1.455 0.335
*P(df = 1) 1.000 0.292 1.000
* P-values were calculated using Fisher’s exact test.
Table 5 Genotype frequencies of rs5148417 and
rs5148418 in non-del patients (n = 199), controls (n =
139) and Han Chinese in 1000 Genome Project (n = 197)
SNP Genotype frequency (%(n)) Genotype frequency (%(n))
Non-del control control 1000GPD
rs5748417
TT 48.7(97) 35.3(49) 35.3(49) 44.2(87)
TC 39.7(79) 47.5(66) 47.5(66) 43.7(86)
CC 11.6(23) 17.3(24) 17.3(24) 12.2(24)
HWE_P 0.801 1.000 1.000 0.975
c
2 6.522 3.337
*P(df = 2) 0.038 0.189
rs5748418
GG 50.3(100) 35.3(49) 35.3(49) 44.2(87)
GA 40(80) 47.5(66) 47.5(66) 43.7(86)
AA 9.5(19) 17.3(24) 17.3(24) 12.2(24)
HWE_P 1.000 1.000 1.000 0.975
c
2 9.013 3.337
*P(df = 2) 0.011 0.189
* P-values were calculated using Fisher’s exact test.
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Page 7 of 9To date, multiple phenotypic features and associated
abnormalities have been observed in patients with the
22q11.2 deletion. However, no consistent correlation
between the genotype and phenotype has been shown
for this syndrome. Rauch et al. conjectured that cono-
truncal cardiac defects related to the 22q11.2 deletion
are usually associated with the common 3 Mb or 1.5
Mb proximally nested deletions, both of which involve
the TBX1 gene [11]. This study shows that all deletion
types are found in the commonly deleted region, impli-
cating the involvement of the TBX1 gene. However, a
detailed analysis of the clinical manifestations did not
reveal any genotype-phenotype correlations in the sub-
jects of our study (Table 2).
TBX1 is thought to be a major candidate gene that
influences the cardiac phenotype or its severity in
patients carrying the 22q11.2 deletion [28]. Its dose-
dependent role in heart development has been demon-
strated in mouse models [29]. Therefore, screening of
the TBX1 gene on the residual 22q11 homologous chro-
matid would likely indicate whether the sequence var-
iants or mutations of the remaining TBX1 copy would
have an impact on the phenotype, thereby revealing pos-
sible correlations between the TBX1 genotype and car-
diac phenotype. No mutations were found in this group
of patients, but eight sequence variants were found in
the haploid TBX1 gene. When comparing the del22q11
CTD patients to the non-del CTDs patients, the fre-
quencies of polymorphism c.933A > G (rs41298840) in
the del22q11 patients significantly differed from that in
the non-del22q11 CTD patients and healthy controls (P
< 0.05). The non-synonymous SNP rs41298838 (c.928G
> A, G310S), which is a known mutation [12] previously
predicted to be a tolerant polymorphism [16], was found
in both the non-del22q11 CTD patients and healthy
controls at similar frequencies. Prior studies have found
that although the TBX1
G310S mutation does not prevent
transactivation, it does prevent the TBX1-SMAD1 inter-
action [30,31], which may have had an impact on the
homeostasis of the cardiac progenitor cells [32]. These
differences imply that the loci rs41298838 and
rs41298840 may have an impact on the pathogenesis of
this syndrome. However, the findings presented may be
biased due to the small number of del22q11 patients
studied.
The allele and genotype frequencies of SNPs
rs5748417 (c.-87+242T > C) and rs5748418 (c.-87+256G
> A) were significantly different between the non-
del22q11 CTDs patients and controls. The alleles c.-87
+242T and c.-87+256G were more frequent in the
group of non-del22q11 patients with CTDs than in con-
trols. These differences suggest the association of these
SNPs in the pathogenesis of CTDs. However, further
studies are needed to clarify the mechanism, especially
since both of the SNPs are located within the 5’UTR
intron of the TBX1 gene.
Conclusions
CTDs, especially PA/VSD and TOF, are the most com-
mon disorders associated with the 22q11.2 deletion syn-
drome. MLPA using commercial kits is a rapid, reliable,
and cost-effective method for the diagnosis of 22q11DS.
Almost all del22q11 CTD patients identified in this
study have a deletion region (typical or atypical) in the
TBX1 gene. The differences in allele and genotype fre-
quency distributions of rs5748417 and rs5748418
between non-del22q11 CTD patients and controls imply
that the genetic variation in the TBX1 gene may be
associated with CTDs. Although the TBX1 gene poly-
morphisms on the residual 22q11 homologous chroma-
tid have not been found to be a major modifier for the
pathogenesis of 22q11.2 deletion syndrome in previous
studies [33,34], the fact that frequencies of the SNPs
rs41298838 and rs41298840 in del22q11.2 CTD patients
differed from those in the non-del CTDs patients in this
study indicated that polymorphisms of the residual
TBX1 gene may have an impact on the pathogenesis of
this syndrome. Further studies with larger sample sizes
are warranted to determine if this notion holds true.
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